Avid Bioservices Inc (CDMO)

[biopharm]

Notch Signaling and its modification by targeting flipped-PS:

We demonstrated that increased activity of casein kinase 2 (CK2) observed in HPC and in MDSC could be responsible for the phosphorylation of Notch and downregulation of Notch signaling. Inhibition of CK2 by siRNA or by pharmacological inhibitor restored Notch signaling in myeloid cells and substantially improved their differentiation, both in vitro and in vivo. This study demonstrates a novel mechanism regulation of Notch signaling in cancer.

Notch Signaling and how this pathway is modified and effects the immune system looks to be the key that proves Bavi works well.

The previous post I pointed out that Dr. Dmitry Gabrilovich will be in Mykonos, Greece on June 25-27, 2014 speaking about the "Effects of Notch Signaling on Regulation of Myeloid Cell Differentiation in Cancer". I still believe this is related or I should say "CAN DIRECTLY" be related to prove that the targeting of PS indeed, changes notch signaling, and therefore--- as stated on Peregrines >> "Signaling Changes Initiated". This is directly from the "Mechanism of Action" section of Peregrines website:

http://www.peregrineinc.com/technology/bavituximab-oncology/mechanism-of-action.html

------------------------------------------------------------

This was talked about here as well--by GoodJohnHunting on a good day where Bavi is King, well... yes, King has Bavi (patents) : )

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87877117&txt2find=notch|signalling

-----------------------------------------------------------

Important:

Notch signalling in the regulation of peripheral T-cell function: this publication helped pave some more understanding of "Notch Signaling"

..it is stated on page 2 of 8 on the right hand side:

"It is this ability of the Notch pathway to modify a cells response to co-incident signals that makes it potentially an important regulator of the peripheral immune system, where cells are consistently required to respond to environmental stimuli to generate an appropriate immune response."

http://www3.imperial.ac.uk/portal/pls/portallive/docs/1/41640.PDF?ev=pub_ext_prw_xdl

-------------------------------------------------------------

Now the publication above is from 2003, where time and time again, its been proven that Notch Signaling or pathway can be modified via "co-incident" signals. It seems that Dr. Dmitry Gabrilovich is setting the stage to clearly point out how Notch signaling should be paid close attention to and when it is modified to allow for a "far greater" immune response than ever seen before. Then, ask yourself what is being targeted and by what ?

flipped-PS is being targeted and the MAB is Bavituximab.

Is it me? ... or are they trying to ignore Bavi... and go back to basics and then show why Bavituximab is on the verge of being part of a scientific breakthrough, in how we can fine tune our immune system!

No different than a math formula and the professor wants to give you the fundamentals on how that formula was derived. Once it becomes second hand knowledge... all that will be talked about is Bavi that targets flipped-PS and it is the target.